OrthoPediatrics Corp. (NASDAQ:KIDS) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 3.8% in the fourth quarter, Holdings Channel reports. The fund owned 57,710 shares of the company’s stock after purchasing an additional 2,099 shares during the period. Bank of New York Mellon Corp’s holdings in OrthoPediatrics were worth $1,338,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Quarry LP acquired a new stake in shares of OrthoPediatrics in the 3rd quarter worth $25,000. R Squared Ltd acquired a new stake in shares of OrthoPediatrics during the 4th quarter worth about $48,000. BNP Paribas Financial Markets increased its position in shares of OrthoPediatrics by 125.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock worth $94,000 after purchasing an additional 1,929 shares during the last quarter. Quantbot Technologies LP boosted its holdings in OrthoPediatrics by 42.2% during the 3rd quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock valued at $157,000 after acquiring an additional 1,712 shares during the period. Finally, AlphaCentric Advisors LLC purchased a new position in OrthoPediatrics during the 4th quarter valued at about $171,000. 69.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

KIDS has been the subject of several recent research reports. Truist Financial decreased their price objective on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Needham & Company LLC restated a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a research note on Wednesday, March 5th. Finally, Stifel Nicolaus decreased their target price on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, March 5th.

Insiders Place Their Bets

In other OrthoPediatrics news, insider Gregory A. Odle sold 5,359 shares of the business’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $133,224.74. Following the sale, the insider now directly owns 148,788 shares in the company, valued at approximately $3,698,869.68. The trade was a 3.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David R. Bailey sold 6,620 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $164,573.20. Following the completion of the sale, the chief executive officer now owns 319,155 shares in the company, valued at $7,934,193.30. This represents a 2.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,732 shares of company stock worth $589,978. 31.80% of the stock is owned by corporate insiders.

OrthoPediatrics Trading Down 2.2 %

KIDS opened at $24.97 on Monday. The firm has a market cap of $606.45 million, a price-to-earnings ratio of -20.30 and a beta of 1.22. OrthoPediatrics Corp. has a 52 week low of $21.02 and a 52 week high of $35.99. The business’s 50 day moving average is $24.85 and its two-hundred day moving average is $25.41. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The firm had revenue of $52.67 million for the quarter, compared to the consensus estimate of $51.16 million. During the same period in the previous year, the business earned ($0.23) earnings per share. On average, research analysts predict that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.